Mario Sznol, M.D.

Dr. Mario Sznol is a Professor of Medicine (Medical Oncology) at Yale and Co-Director of the Cancer Immunology Program and Leader of the Melanoma/Renal Cancer Translational Research Team at Yale Cancer Center. Dr. Sznol, formerly with the National Cancer Institute (NCI), has an international reputation in cancer drug development. His expertise and experience are in cancer immunotherapy, drug development for cancer and treatment of patients with melanoma and renal cell carcinoma. Dr. Sznol has contributed to the development of cytokines, cell therapies, co-stimulatory antibodies and immune checkpoint inhibitors, through the design, execution and analyses of clinical trials and clinical development plans as well as through direct patient care.

After completing a fellowship in medical oncology at Mount Sinai College of Medicine in 1987, he joined the NCI as a Senior Investigator in the Investigational Drug Branch (IDB), Cancer Therapy Evaluation Program (CTEP). From 1994-1999, Dr. Sznol was head of the Biologics Evaluation Program, IDB, CTEP where he was responsible for clinical development of multiple biological and immune therapy agents. In 1999, he left NCI to become Vice President of Clinical Development for Vion Pharmaceuticals. He joined the Yale faculty in medical oncology in 2004.

• Lieping Chen, M.D., Ph.D.
• Mario Sznol, M.D.

• Stephen Miller, Ph.D.

• Ursula Matulonis, M.D.

• Weiping Zou, M.D, Ph.D.

• Brahm Segal, M.D.

• Lisa M. Coussens, Ph.D.